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Incidence and Risk Factors of Arrhythmic Events in
Catecholaminergic Polymorphic Ventricular Tachycardia
Meiso Hayashi, MD; Isabelle Denjoy, MD; Fabrice Extramiana, MD, PhD; Alice Maltret, MD;
Nathalie Roux Buisson, MD; Jean-Marc Lupoglazoff, MD, PhD; Didier Klug, MD;
Miyuki Hayashi, MD; Seiji Takatsuki, MD; Elisabeth Villain, MD; Joël Kamblock, MD;
Anne Messali, MD; Pascale Guicheney, PhD; Joël Lunardi, MD, PhD; Antoine Leenhardt, MD
Background—The pathophysiological background of catecholaminergic polymorphic ventricular tachycardia is well
understood, but the clinical features of this stress-induced arrhythmic disorder, especially the incidence and risk factors
of arrhythmic events, have not been fully ascertained.
Methods and Results—The outcome in 101 catecholaminergic polymorphic ventricular tachycardia patients, including 50
probands, was analyzed. During a mean follow-up of 7.9 years, cardiac events defined as syncope, aborted cardiac arrest,
including appropriate discharges from implantable defibrillators, or sudden cardiac death occurred in 27 patients,
including 2 mutation carriers with normal exercise tests. The estimated 8-year event rate was 32% in the total population
and 27% and 58% in the patients with and without -blockers, respectively. Absence of -blockers (hazard ratio [HR],
5.48; 95% CI, 1.80 to 16.68) and younger age at diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89) were
independent predictors. Fatal or near-fatal events defined as aborted cardiac arrest or sudden cardiac death occurred in
13 patients, resulting in an estimated 8-year event rate of 13%. Absence of -blockers (HR, 5.54; 95% CI, 1.17 to 26.15)
and history of aborted cardiac arrest (HR, 13.01; 95% CI, 2.48 to 68.21) were independent predictors. No difference was
observed in cardiac and fatal or near-fatal event rates between probands and family members.
Conclusions—Cardiac and fatal or near-fatal events were not rare in both catecholaminergic polymorphic ventricular
tachycardia probands and affected family members during the long-term follow-up, even while taking -blockers, which
was associated with a lower event rate. Further studies evaluating concomitant therapies are necessary to improve
outcome in these patients. (Circulation. 2009;119:2426-2434.)
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Catecholaminergic polymorphic ventricular tachycardia(CPVT) is a familial arrhythmogenic disorder character-
ized by polymorphic ventricular tachyarrhythmias induced by
physical or emotional stress without any detectable morpho-
logical abnormalities of the heart.1,2 Mutations in genes
encoding cardiac ryanodine type 2 receptor (RYR2)3,4 and
calsequestrin 2 (CASQ2)5,6 have been identified and are
recognized as causing the autosomal-dominant and -recessive
forms of CPVT, respectively. CPVT has become recognized
as a significant cause of sudden cardiac death (SCD) in
children and young adults, particularly in the era of molecular
biology.7,8 Many clinical issues, however, remain to be
clarified. For instance, the incidence of arrhythmic events
occurring during -blocker treatment varies among published
reports.2,9–14 Likewise, little is known about the influence of
prior cardiac symptoms or the patient’s age on the occurrence
of tachyarrhythmias, and few data are available on the
importance of family screening, including genetic examina-
tions. To address these issues and to clarify the risk factors of
cardiac events, we conducted a multicenter observational
study and analyzed a large series of CPVT patients.
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Methods
Study Population
The patients enrolled were probands and family members referred to
the study centers for genetic arrhythmias. Symptoms such as aborted
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cardiac arrest (ACA), syncope with or without seizures, and palpi-
tations were investigated. Patients underwent a 12-lead ECG, 24-
hour Holter ECG, 2-dimensional echocardiography, and an exercise
stress test unless they had significant physical limitations. Exercise
stress tests were performed with a Bruce protocol on a treadmill or
as a graded, continuous test to maximal effort on a cycle ergometer.
Intravenous catecholamines were administered if necessary. The
diagnosis of CPVT was based on the criteria we previously pub-
lished, which, in short, required stress-induced reproducible ventric-
ular arrhythmias in patients with a normal resting ECG and no
detectable structural heart abnormalities.2 Family screening was
performed and blood samples were obtained from those who agreed
to a genetic evaluation and provided written consent. The diagnosis
of CPVT was made either on a clinical basis or after identification of
a mutation in the RYR2 or CASQ2 gene. Patients with positive
genetic results without any clinical symptoms or signs were defined
as silent genetic mutation carriers.
None of the probands or family members reported in our previous
publications1,2 were included. Twenty-eight patients from 8 families
with RYR2 mutations11 and 6 patients from 2 families with CASQ2
mutations6 who were previously reported were included. Patients
55 years of age at the time of diagnosis were excluded to reduce
the chance of including age-related events unlinked to CPVT.
Genetic Analysis
Genomic DNA was extracted from peripheral blood leukocytes using
standard methods. A targeted mutational analysis of 57 exons of the
RYR2 gene was performed, covering areas with known function or
mutations (exons 8 to 10, 14, 15, 22, 25, 27, 28, 29, 31, 34, 37, 38,
40 to 49, 51, 56, 59 to 64, 68, 70 to 73, 75, 83, 88 to 105). The coding
regions were amplified with polymerase chain reaction and analyzed
by denaturing high-performance liquid chromatography (WAVE,
Transgenomic Inc, Omaha, Neb). Samples exhibiting abnormal
profiles were analyzed by unidirectional sequencing with a 3100
BigDye Terminator version 3.1 sequencing kit and ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Foster City, Calif). All
sequence variants were reamplified and resequenced to exclude
polymerase errors. When putative mutations were detected, denatur-
ing high-performance liquid chromatography analysis was per-
formed on 200 samples (400 alleles) of genomic DNA from healthy
and unrelated subjects to exclude DNA polymorphisms. In the
patients without any identified mutations in the RYR2 gene, all 11
exons of the CASQ2 gene also were screened using intronic
primers and analyzed by denaturing high-performance liquid
chromatography.
Patient Follow-Up
After the diagnosis was confirmed, all patients (and their parents
when appropriate) were strongly advised to avoid any strenuous
physical activity according to the recommendations15 and were
followed up every 6 to 12 months at the referring centers. The
follow-up period was counted from the date of diagnosis to the date
of the last visit or the patient’s death. The therapy, ie, drugs and
implantable defibrillators (ICDs), depended on each individual
physician. The dosage of the drug was determined from the patient’s
body weight and was adjusted during follow-up. The incidence of
cardiac events, defined as any syncope under physical or emotional
stress, ACA, including appropriate ICD discharges, or SCD during
follow-up, and the incidence of fatal or near-fatal events, defined as
ACA or SCD, were evaluated. Risk factors of those events also were
assessed.
Statistical Analysis
Continuous variables, expressed as meanSD, were compared by
use of an unpaired t test; categorical variables were compared by use
of Fisher’s exact test. The time to the first occurrence of a cardiac or
fatal or near-fatal event was expressed visually with the use of
Kaplan-Meier curves and assessed with the log-rank test when
appropriate.16 The estimated 4- and 8-year event rates are presented.
The time to event occurrence also was analyzed with Cox
proportional-hazards models.17 Variables examined included gender,
age at diagnosis, proband, cardiac symptoms before the diagnosis,
identification of a mutation in the RYR2 or CASQ2 gene, silent
genetic mutation carrier, and absence of -blockers. A single-vari-
able analysis was conducted first, and a multivariable analysis
adjusted for variables with a single-variable value of P0.20 was
performed. Relative risks were expressed as hazard ratios (HRs) with
95% CIs. The data for patients who were lost to follow-up were
analyzed up to the last contact. With regard to -blockers, all
analyses were performed according to the intention-to-treat princi-
ple. All probability values were based on 2-sided tests and were
considered significant at P0.05. All analyses were conducted with
SPSS version 11.0 software (SPSS Inc, Chicago, Ill).
Results
Characteristics of the Study Subjects
As of March 2008, 50 probands and 51 family members were
enrolled. All probands and 34 family members were diag-
nosed on a clinical basis; the other 17 family members were
silent genetic mutation carriers. Table 1 shows their baseline
characteristics. The age at diagnosis was 1510 years (range,
2 to 51 years). Cardiac symptoms before the diagnosis were
reported in 61 patients (60%): in all probands and 11 family
members. Among the 61 patients with symptoms before
diagnosis, 57 patients (93%) were symptomatic before 21
years of age, and the diagnosis of CPVT was made with a
delay of 2.64.4 years. In the present CPVT cohort, the rate
of experiencing cardiac symptoms before the diagnosis was
35% and 72% at 10 and 20 years of age, respectively (Figure
1). Seizures were observed in 15 patients, 8 of whom were
considered to have drug-resistant epilepsy until the diagnosis
of CPVT. In 23 of the 40 family members without any prior
cardiac symptoms, reproducible ventricular arrhythmias were
recorded during exercise. During the exercise testing (n91),
ventricular tachycardia, couplets, and frequent isolated pre-
Table 1. Baseline Characteristics of the 101 Patients
Proband, n 50
Family member, n 51
Male gender, n 54
Age at first symptom, y 128
Age at diagnosis, y 1510
10, n 39
11–20, n 42
21, n 20
Severest symptom before the diagnosis, n
Syncope 45
Aborted cardiac arrest 11
Palpitations or near syncope 5
Asymptomatic before diagnosis, n 40
Corrected QT interval, ms 40321
Mutation, n
RYR2 72
CASQ2 7
Not identified, n 16
Not analyzed, n 6
Silent genetic mutation carrier, n 17
Continuous variables are expressed as meanSD.
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mature ventricular beats were induced in 27 (30%), 14 (15%),
and 38 patients (42%), respectively. The exercise test was
negative in 12 asymptomatic family members with a positive
genotype (6 male patients; age, 1814 years). These 12
patients and another 5 genetically affected asymptomatic
family members who did not undergo exercise stress testing
were considered silent genetic mutation carriers. Cardiac
magnetic resonance imaging was performed in 3 patients,
showing normal results.
Molecular analysis identified 28 different RYR2 and 3
different CASQ2 mutations (Figure 2). Forty-four probands
underwent genetic screening, and RYR2 and CASQ2 muta-
tions were found in 31 and 3, respectively. This screening
yielded an overall rate of 77% for the detection of mutation
even with a limited analysis of 57 exons of RYR2 gene. All
family members included underwent a genetic examination,
identifying mutant RYR2 and CASQ2 genes in 41 and 4,
respectively.
Incidence of Cardiac and Fatal
or Near-Fatal Events
During a follow-up of 7.94.9 years, 27 patients (27%)
experienced cardiac events (Figure 3). The first cardiac event
occurred 5.24.3 years after the diagnosis, and 10 of the 27
patients (37%) who had cardiac events during follow-up had
events1 (Table 2). The trigger of the first cardiac event was
physical activity in 12 patients, emotional stress in 10, and
unknown in 5, including 4 with SCD (Table 2). Fatal or
near-fatal events developed in 13 of those 27 patients and
were observed at between 13 and 26 years of age in 12 of the
13 patients (92%). A fatal or near-fatal event was the first
event during follow-up in 9 patients, including 5 SCDs (Table
2). The estimated 4- and 8-year event rates for cardiac events
were 12% and 32%, respectively, and those for fatal or
near-fatal events were 4% and 13%, respectively (Figure 4A).
Cardiac events were observed in 15 probands and 12
family members, including 2 silent genetic mutation carriers
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Figure 1. Kaplan-Meier survival curve. Solid line
shows the symptom-free survival curve before the
diagnosis of CPVT. Cardiac symptoms before the
diagnosis were noted in 61 of the 101 study
patients.
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Figure 2. Schematic representation of a RYR2
(A) and CASQ2 (B) with mutations identified in
the present study. A number indicating the
position of the amino acid and the single-letter
amino acid codes were used to denote the
mutations. 27X indicates a stop codon 27
amino acids downstream from the deletion.
The yellow bands in A indicate the 4 discrete
regions in which the mutations described thus
far have been found to cluster. The orange
mutations indicate those identified in the
patients experiencing cardiac events under
-blockers during the follow-up. Mutations in
bold have not been reported. *G4662S was
identified in the patients also with an H4762P
mutation.
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with negative results on the exercise stress test, who were not
treated with -blockers. No difference was seen in the cardiac
or fatal or near-fatal event rate between the probands and
family members both in the total study population and in the
subgroup of patients treated with -blockers.
There were 37 asymptomatic patients with a positive
genotype. During follow-up, cardiac events were observed in
9 of these 37 patients (24%) and in 18 of the other 64 patients
(28%). No differences were observed in cardiac event rate
(log-rank P0.58) and fatal or near-fatal event rate (log-rank
P0.86) between these 2 groups.
-Blocker Therapy
-Blockers were administered immediately after the diagno-
sis in 81 patients (80%) (Figure 3): nadolol in 63 and other
-blockers in 18. The most frequent reason that -blockers
were not prescribed was an absence of cardiac symptoms or
stress-induced ventricular tachycardia; this was the case for
14 of the 20 untreated patients. In 8 patients, the physician
changed the type of -blocker because of insufficient drug
efficacy during follow-up.
Among 81 patients on -blockers, 62 (77%) experienced
no events during follow-up (Figure 3). The other 19 patients
experienced cardiac events, but at least 6 of them (32%) did
not take the drug on the day of the event (Table 2). The
estimated 4- and 8-year cardiac event rates were 8% and 27%,
respectively, in the patients with -blockers and 33% and
58%, respectively, in those without (log-rank P0.01) (Fig-
ure 4B). Fatal or near-fatal events occurred in 9 of the 81
patients on -blockers (11%), and at least 4 of the 9 patients
(44%) did not take the drug on the day of the event. The
estimated 4- and 8-year fatal or near-fatal event rates were 1%
and 11%, respectively, in the patients with -blockers and
18% and 25%, respectively, in those without (log-rank
P0.05) (Figure 4C).
Nadolol was used with a latest dosage of 1.60.9 mg/kg.
Cardiac events during follow-up were observed in 12 of 63
patients (19%) with nadolol and in 7 of 18 patients (39%)
with -blockers other than nadolol. In 2 of 3 patients
experiencing SCD on nadolol, the dosage at that time was
1.0 mg/kg (Table 2).
Risk Factors of Cardiac and Fatal
or Near-Fatal Events
Table 3 shows the predictors for cardiac and fatal or near-fatal
events using a Cox proportional-hazards analysis. A multiva-
riable analysis revealed that younger age at the time of
diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89;
P0.02) and absence of -blockers (HR, 5.48; 95% CI, 1.80
to 16.68; P0.003) were independent predictors for cardiac
events. In addition, a history of ACA before the diagnosis
(HR, 13.01; 95% CI, 2.48 to 68.21; P0.002) and absence of
-blockers (HR, 5.54; 95% CI, 1.17 to 26.15; P0.03) were
independent predictors for fatal or near-fatal events. Syncopal
history before the diagnosis was not associated with higher
cardiac or fatal or near-fatal event rates.
In the subgroup of 81 patients receiving -blockers,
-blockers other than nadolol (HR, 3.12; 95% CI, 1.16 to
8.38; P0.02) and younger age at diagnosis (HR, 0.31 per
decade; 95% CI, 0.14 to 0.69; P0.004) were independent
predictors for cardiac events.
Therapies Other Than -Blockers
Verapamil was added to the -blockers in 4 patients, who
remained event free during the next 1.60.6 years. An ICD
was implanted immediately after diagnosis in 4 patients and
5.84.2 years after diagnosis in 12 patients because of
syncope in 6, ACA in 2, and ventricular arrhythmias provo-
cable during the exercise stress test despite -blocker therapy
in 4. The age at the ICD implantation was 2011 years (8
male and 8 female patients). In all patients, the ICD was
initially programmed with 1 ventricular fibrillation zone with
a detection interval of 300 ms. Among 16 patients with an
ICD, appropriate shocks were delivered in 4 patients (25%),
and inappropriate shocks were noted in 6 patients (38%):
resulting from sinus tachycardia in 4 and lead fractures in 2.
The follow-up period after the diagnosis in the patients with
an ICD was 9.04.4 years, and no patients died during
3.92.8 years of follow-up after the ICD implantation.
Exercise Stress Tests During the Follow-Up
Data from the exercise stress test during the follow-up were
obtained in 70 patients: 1, 2, and 3 tests in 11, 29, and 30
patients, respectively. The tests were performed with a
treadmill or ergometer in 33 and 37 patients, respectively.
Cardiac events developed in 21 of the 70 patients (30%). The
latest results, which were the results just before the cardiac
events in the patients experiencing them, were couplets or
more successive premature ventricular contractions in 13 of
the 21 patients with cardiac events and 16 of the 49 patients
without (62% versus 33%; sensitivity, 0.62; specificity, 0.67;
P0.03). Other arrhythmias provoked were not significantly
associated with future cardiac events.
Before the Diagnosis
61 Symptomatic
Patients
40 Asymptomatic
Patients
During the Follow-up
Cardiac Events
19 Patients
with BBLs
No Event
62 Patients
with BBLs
Cardiac Events
8 Patients
without BBLs
No Event
12 Patients
without BBLs
14
43
0
12
4
19
Diagnosis
BBLs
24
BBLs
57
5
2
1
4
3
7
Figure 3. Follow-up results of the study subjects with and with-
out cardiac symptoms before the diagnosis. Twenty-seven
patients who experienced cardiac events during the follow-up
and 74 patients who did not were classified according to the
administration of -blockers (BBLs). The numbers inside the cir-
cles indicate the numbers of patients in each subset; the num-
bers inside the squares, numbers of patients with fatal or near-
fatal events.
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Discussion
Main Findings
The analysis of 101 CPVT patients followed up for 7.94.9
years showed that cardiac events developed in 27 patients
(27%), including 13 patients with fatal or near-fatal events
(13%), which gave an estimate for the 8-year cardiac and fatal
or near-fatal event rates of 32% and 13%, respectively. In
most of the patients (12 of the 13 patients [92%]), a fatal or
near-fatal event occurred at between 13 and 26 years of age.
In the multivariable analyses, absence of therapy with any
-blockers was an independent predictor for cardiac events,
as well as younger age at the time of the diagnosis, and was
an independent predictor for fatal or near-fatal events, as well
as a history of ACA. No difference was observed in the
cardiac or fatal or near-fatal event rate between the probands
and family members, between the patients with and without a
prior syncopal event, or between the asymptomatic patients
with a positive genotype and the other patients.
Incidence of Arrhythmias
In studies2,9 –14 following up 10 CPVT patients, the
occurrence of cardiac events varied from 2% to 62% of the
Table 2. Breakthrough in the Patients Experiencing Cardiac Events
Patient Sex
Proband or Family
Member
Age at
Diagnosis,
y
Genetic
Result
First Cardiac Event
During Follow-Up
and BBL
Compliance
Age at the
Event, y
BBL at the
Event
Dosage of BBL,
mg (mg/kg)
Therapeutic Option
After the First
Event
Recurrent Cardiac Event
During Follow-Up
1 Female Family member 10 RYR2 Syncope 15 Nadolol 120 (2.1) ICD implantation ICD shock
2 Female Proband 12 RYR2 Syncope while
stopping BBL
17 Nadolol 120 (1.7) None Aborted SCD while
stopping BBL
3 Female Family member 11 RYR2 Syncope while
stopping BBL
16 Nadolol 80 (1.6) None Syncope
4 Male Family member 10 RYR2 Syncope 18 Nadolol 120 (1.8) None None
5 Male Proband 11 Not
identified
Syncope after
forgetting BBL
13 Nadolol 40 (1.0) Nadolol was
increased
Syncope
6 Female Family member 4 Not
identified
Syncope 4 Acebutolol 100 (5.0) Verapamil was
added
None
7 Male Family member 9 RYR2 Syncope 10 Nadolol 60 (1.4) ICD implantation None
8 Female Proband 6 CASQ2 Syncope 14 Nadolol 240 (5.3) ICD implantation None
9 Male Proband 7 RYR2 Syncope 13 Nadolol 80 (2.2) ICD implantation None
10 Female Proband 6 RYR2 Syncope after
forgetting BBL
14 Bisoprolol 7.5 (0.1) None Syncope
11 Female Proband 4 RYR2 Syncope 13 Nadolol 80 (1.6) Atenolol was
started
Aborted SCD after
forgetting BBL
12 Male Family member 9 RYR2 Syncope 11 Nadolol 80 (2.0) None None
13 Female Proband 20 Not analyzed Syncope 21 Bisoprolol 5 (0.1) ICD implantation None
14 Male Family member 16 RYR2 Aborted SCD while
stopping BBL
22 Acebutolol 200 ICD implantation None
15 Male Proband 7 RYR2 SCD 14 Propranolol 90 (2.0)
16 Male Proband 18 RYR2 SCD 20 Pindolol 7.5
17 Male Family member 16 RYR2 SCD 22 Nadolol 40 (0.6)
18 Male Proband 12 Not
identified
SCD 26 Nadolol 160 (1.7)
19 Male Proband 16 RYR2 SCD while
stopping BBL
36 Nadolol 80 (0.9)
20 Female Family member 5 RYR2 Syncope 9 No Nadolol was
started
None
21 Female Family member 26 RYR2 Syncope 30 No Nadolol was
started
None
22 Male Family member 5 RYR2 Syncope 11 No Nadolol was
started
None
23 Male Family member 12 RYR2 Syncope 14 No None Aborted SCD
24 Female Proband 18 RYR2 Syncope 24 No None Syncope
25 Male Proband 15 Not analyzed ICD shock* 16 No Bisoprolol was
started
ICD shock
26 Female Proband 14 Not
identified
ICD shock 19 No Nadolol was
started
ICD shock after
forgetting BBL
27 Male Proband 24 Not analyzed ICD shock 25 No Atenolol was
started
None
BBL indicates -blocker.
*ICD shock means appropriate discharge of an ICD.
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subjects (Table 4). Those reports included both probands
and family members, and most patients received
-blockers. The difference in the incidence of cardiac
events between the present study and others may be
attributable to the difference in the type, dosage, or
compliance with -blockers and possibly to the small
number of subjects in the studies published so far. Those
studies2,9,10,12–14 followed up 50 patients, except for 1
study11 that included 54 patients with only 1 patient
experiencing a cardiac event during a median follow-up of
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Figure 4. Kaplan–Meier survival curves. A, Event-free survival curves of cardiac events (solid line) and fatal or near-fatal events
(dashed line) in the total study population. B, Comparison of the cardiac event rates between the patients with (solid line) and
without (dotted line) -blockers (BBLs). C, Comparison of the fatal or near-fatal event rates between the patients with (solid line)
and without (dotted line) -blockers.
Table 3. Predictors for Developing Cardiac Events and Fatal or Near-Fatal Events Using Cox Proportional-Hazards Analyses
Cardiac Events Fatal or Near-Fatal Events
Single-Variable Analysis Multivariable Analysis Single-Variable Analysis Multivariable Analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Male gender 1.25 (0.58–2.68) 0.57 2.30 (0.71–7.50) 0.17
Age at diagnosis (per decade) 0.56 (0.34–0.94) 0.03 0.54 (0.33–0.89) 0.02 0.81 (0.44–1.52) 0.52
Proband 0.96 (0.44–2.07) 0.91 1.56 (0.46–5.27) 0.48
Symptoms before diagnosis
None 1.00 1.00 1.00 1.00
Syncope 0.98 (0.41–2.35) 0.96 1.57 (0.51–4.76) 0.43 0.78 (0.17–3.69) 0.76 1.84 (0.29–11.57) 0.52
ACA 2.47 (0.82–7.43) 0.11 2.97 (0.91–9.76) 0.07 6.68 (1.53–29.07) 0.01 13.01 (2.48–68.21) 0.002
Mutations
Not determined 1.00 1.00
RYR2 1.05 (0.43–2.56) 0.91 0.85 (0.25–2.89) 0.79
CASQ2 0.36 (0.04–2.93) 0.34 0.00 (0.00–?*) 0.98
Silent genetic mutation carrier 0.65 (0.15–2.79) 0.56 0.04 (0.00–151.69) 0.44
Absence of -blockers 2.85 (1.22–6.67) 0.02 5.48 (1.80–16.68) 0.003 3.39 (0.95–12.07) 0.06 5.54 (1.17–26.15) 0.03
*The upper confidence limit could not be estimated because of low event rates.
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2 years. A longer follow-up period, however, may be
necessary to ascertain the occurrence of cardiac events in
CPVT because the first cardiac event occurred 5.24.3
years after diagnosis in the present study.
The present study also demonstrated that syncopal history
before diagnosis was not associated with higher cardiac or
fatal or near-fatal event rates during the follow-up, although
history of ACA was an independent predictor for fatal or
near-fatal events (Table 3). This result should be taken into
consideration for risk stratification in patients diagnosed
with CPVT. We think that -blockers should be prescribed
in every CPVT patient regardless of any prior syncopal
events.
Effectiveness of -Blockers
-Blockers have empirically been considered the best thera-
peutic option in CPVT,1,2 but to the best of our knowledge, no
study has compared event rates between patients with and
without -blockers. In the present study, we confirmed
significantly lower cardiac and fatal or near-fatal event rates
in the patients with -blockers. Nonetheless, the 8-year
cardiac and fatal or near-fatal event rates in the patients with
-blockers were not sufficiently low (27% and 11%, respec-
tively). This incomplete effect of -blockers may be attrib-
utable, at least in part, to poor drug compliance, which was
observed in some patients experiencing those events and was
shown in our previous report.2 Physicians must keep patients
aware that missing even a single dose can provoke lethal
arrhythmias. The type of -blockers also could have influ-
enced the outcome. Although treatment was not randomized,
the present study suggests that taking -blockers other than
nadolol could be associated with higher event rates. It is
noteworthy that, in 3 of 5 SCDs occurring in patients taking
nadolol, 2 patients took a low dosage (Table 2). These results
suggest that nadolol is a recommendable drug for CPVT
patients when used with a sufficient dosage (1.5 mg/kg).
Furthermore, incomplete drug therapy may be attributable to
the absence of reliable tests to ascertain its efficacy. Results
of exercise stress tests during follow-up were significantly
associated with future cardiac events, but the sensitivity and
specificity were not sufficiently high, suggesting that the
exercise stress test can be used only as a moderate guide for
therapy efficacy, although it is useful for diagnosing
CPVT.1,2,9,11–14
Therapeutic Option Added to -Blockers
Two studies18,19 reported that verapamil added to -blockers
suppressed ventricular arrhythmias in the CPVT patients
during the exercise stress test, suggesting its beneficial effect
in combination with -blockers. ICDs can be another thera-
peutic option despite the potential drawbacks in young
patients20 and concern about provoking arrhythmic storms.21
A recent case series22 also showed the efficacy of left cardiac
sympathetic denervation, which was not performed in any
patients in the present study. We could not assess the role of
verapamil because of the small number of patients treated
with this drug. Further studies are necessary to elucidate the
clinical efficacy of those therapeutic options in CPVT. The
results of the present study suggest that those additional
therapies should be discussed, especially for young patients,
those with history of ACA, or those with poor -blocker
efficacy or compliance.
Family Screening
To the best of our knowledge, no study has separately
evaluated the incidence of arrhythmic events between pro-
bands and family members. We found a similar event rate in
analyses both with and without adjustment for the treatment
with -blockers; we also observed, as others9 did, that cardiac
events occurred in silent genetic mutation carriers with
normal exercise stress tests. These results underline the
importance of family screening, including genetic testing, and
strongly suggest that genetically positive family members
should receive -blockers even after a negative exercise test,
which can change with time.9,14
Age and Risk of Arrhythmias
The present study demonstrated that a younger age at the
CPVT diagnosis was an independent predictor of future
cardiac events. The background of the relationship between
age and arrhythmia risk is uncertain and probably multi-
factorial. It is speculated that children have more oppor-
Table 4. Publications Demonstrating Follow-Up Results of >10 CPVT Patients
Year
Published
Study Subjects, n
Mean Follow-Up,
y
Patients Treated With BBLs,
n (%)
Patients With Cardiac Events,
n (%)
Patients With SCD,
n (%)Proband Family Member
Leenhardt et al2 1995 20 1 7.0 21 (100) 3 (14) 2 (10)
Swan et al14 1999 14 (in 2 families) 8.0 14 (100) 1 (7) 0
Lahat et al10 2001 13 (in 7 families) 1.7 13 (100) 2 (15) 0
Bauce et al9 2002 43 (in 8 families) 6.5 26 (60) 1 (2) 1 (2)
Priori et al12 2002 30 9 3.3, 4.3* 39 (100) 18 (46) NA
Sumitomo et al13 2003 25 4 6.8 28 (97)† 18 (62) 7 (24)
Postma et al11 2005 12 42 2.0‡ 50 (93) 1 (2) 1 (2)
Present study 50 51 7.9 81(80)† 27 (27) 5 (5)
BBL indicates -blocker.
*3.3 years in patients with mutation in RYR2 and 4.3 years in nongenotyped patients.
†Patients administered with -blockers immediately after diagnosis.
‡Median follow-up period.
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tunities to engage in strenuous physical activities or to
become excited and that patients with more severe forms
of CPVT, barely suppressed by drugs, are diagnosed
younger in life. Furthermore, -blocker dosage based on
weight might be insufficient in children because many
hepatically eliminated drugs, including -blockers, show
an age-dependent clearance.
Study Limitations
This study has several limitations. First, the therapeutic
management depended on each individual physician, and the
administration of -blockers was not randomized. However,
it seems ethically difficult not to prescribe -blockers in the
CPVT patients. Even in patients with an ICD, -blockers
should not be discontinued because ICDs do not always
terminate CPVT.21 Second, because of the small number of
patients (n19) and the short subsequent follow-up period
(3.12.5 years), we could not draw any definitive conclu-
sions regarding the management of patients after cardiac
events under -blockers. Third, enrollment of family mem-
bers in the present study was subject to potential bias because
family screening based on voluntary participation was not
thoroughly performed.
Conclusions
CPVT is a malignant channelopathy with high cardiac and
fatal or near-fatal event rates in both probands and affected
family members. Prescription of -blockers is associated
with lower event rates but does not provide sufficient
prevention of arrhythmias. Further studies evaluating the
indications and efficacy of concomitant therapies, ie,
verapamil, ICDs, or left cardiac sympathetic denervation,
are necessary to improve outcome in these patients at high
risk for SCD.
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CLINICAL PERSPECTIVE
Catecholaminergic polymorphic ventricular tachycardia is a rarely recognized but important cause of sudden cardiac death
in the young. This multicenter observational study of 101 subjects (50 probands, 51 family members) was conducted to
characterize the clinical course of the disease. Catecholaminergic polymorphic ventricular tachycardia was diagnosed from
clinical features in 84 subjects and from genotyping in 17 subjects. During the follow-up of 7.94.9 years, 27 patients
(27%), including 2 silent gene mutation carriers, experienced syncope, aborted cardiac arrest, or sudden cardiac death
events that were fatal or near-fatal in 13 subjects. The estimated 8-year event rate was 32% with a 13% rate of fatal or
near-fatal events. The event rates between the probands and family members were comparable. A younger age at diagnosis,
a history of aborted cardiac arrest, and the absence of -blockers were predictors of events, but -blocker therapy was not
completely protective. These results suggest that -blockers should be prescribed even if the diagnosis is made from
genotyping when there is not a history of symptomatic arrhythmias. Additional therapies, including implantable
defibrillators, verapamil, or left cardiac sympathetic denervation, should be considered in patients with markers of
increased risk.
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